After years of failed attempts to treat Alzheimer’s disease by targeting a toxic brain plaque called amlyoid, a critical mass of scientists turned their attention to a seemingly more promising target: a tangled cranial protein called tau. But the failure of a closely watched tau treatment suggests history may repeat itself for neurology’s next-best idea.

On Wednesday, the Swiss drug maker AC Immune said its anti-tau antibody missed its primary and secondary goals in a placebo-controlled study that enrolled more than 450 people with early-stage Alzheimer’s. 

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • It’s not “a toxic brain plaque called amlyoid”. Plaques are made of a type of amyloid called amyloid-beta plus other non-amyloid components. And it’s not clear that they’re toxic. They may be a protective reaction to an environmental threat, such as a pathogen or a chemical toxin.

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy